Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Documenti analoghi

• Adverse Impact of Pre‐Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation
  di: Yukiko Misaki, et al.
  Pubblicazione: (2025)
• Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
  di: Akihiko Izumi, et al.
  Pubblicazione: (2025)
• The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
  di: Yutaka Shimazu, et al.
  Pubblicazione: (2024)
• Platelet Recovery and Its Impact on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Nationwide Retrospective Study
  di: Naoki Kurita, et al.
  Pubblicazione: (2025)
• Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma—A Retrospective Multicenter Analysis
  di: T. Richardson, et al.
  Pubblicazione: (2024)